We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Oral Cancer Detection Increased with Saliva Test

By LabMedica International staff writers
Posted on 10 May 2012
A simple saliva test has been created which could identify the presence of biomarkers that are associated with oral cancer.

The easy, cost-effective saliva test to detect oral cancer would be a breakthrough that would drastically improve screening and result in fewer people dying of the world's sixth most common cancer.

A surgical team at Michigan State University (East Lansing, MI, USA) is teaming up with a local area dental benefits firm for a clinical trial of the saliva test that will aid physicians and dentists to know which patients need treatment and which ones could avoid needless and invasive biopsies. The scientists will be looking for certain biomarkers previously identified by researchers at the University of California (UCLA; Los Angeles, CA, USA). The biomarkers have been shown in studies to confirm the presence of oral cancer.

Barry Lloyd Wenig, MD, MPH, PhD, a professor of otolaryngology and lead investigator said, "Most white lesions are benign, so a majority of people who develop them are getting biopsies that are not needed. Conversely, a simple test would allow us to identify those patients with malignant lesions and get them into treatment quicker. These tests are as noninvasive as it gets; patients simply need to spit into a cup. The ease of the test will greatly expand our ability to effectively screen for the cancerous lesions. Right now, there are no early screenings available for most head and neck cancers."

Prof. Wenig is teaming up with Delta Dental (Okemos, MI, USA) which works with scientists from leading universities to monitor advances in science. Their chief science officer, Jed J. Jacobson, DDS, MPH, said, "The results of this trial could be life changing for many people. It is a tremendous opportunity for the dental community to participate in what could be a groundbreaking project.” Oral cancer has a poor survival rate linked to late detection; only 60% of patients live beyond five years after diagnosis. The survival rate is less than 38% among black males.

Related Links:

Michigan State University
University of California
Delta Dental



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
Gold Member
Platelet Function Analyzer
PL-12

Channels

Clinical Chemistry

view channel
Image: A simple daily blood test could help critically ill sepsis patients stop antibiotics sooner, reducing overuse and potentially helping combat antibiotic resistance (Image Credit: Adobe Stock)

Daily Blood Biomarker Testing May Help Guide Earlier Antibiotic Stopping in Sepsis

Sepsis is a life-threatening condition caused by the body’s overwhelming response to infection and accounts for thousands of deaths each year. In intensive care, concern about stopping treatment too early... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: Beginning in 2027, Quest will provide access to the Onclarity Self-Collection Kit through clinician, health plan, and consumer-initiated testing channels, along with its patient service center network.

Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection

Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more